CHI is delighted to announce a new and improved Oligonucleotide & Precision Therapeutics (OPT) Congress for 2019. To complement our 4th annual Oligonucleotide Discovery and Delivery conference we are introducing a 2 day program dedicated to Oligonucleotide CMC and Regulatory Strategies. In addition, we deliver two in-depth symposiums focusing on Drug Discovery for Rare Diseases and New Frontiers in Gene Editing and Repair. Bringing together leading discovery scientists, developers, CMC experts, regulatory specialists and technology providers, OPT Congress provides a unique opportunity to discuss advances in next-generation oligonucleotide therapies throughout the drug development process. Attend in 2019 to optimize your drug design, delivery and performance, accelerate time to market and achieve commercial success.

Speaker proposals for this event are now being accepted - If you would like to submit a proposal to give a presentation at this meeting, please click here.




Key Contacts

FOR CONTENT AND SPEAKER SUGGESTION:

Oligonucleotide Discovery and Development &
Oligonucleotide CMC and Regulatory Strategies
Gemma Smith
Senior Director, Conferences
Cambridge Healthtech Institute
T: +447754.518.131

FOR PARTNERING AND SPONSORSHIP INFORMATION:

Carolyn Cooke, Business Development Manager
Cambridge Healthtech Institute
T: (+1) 781.972.5412 | E: ccooke@healthtech.com

FOR MEDIA PARTNERSHIPS:

Rich Handy, Senior Director, Marketing
Cambridge Healthtech Institute
T: (+1) 781.972.5456 | E: rhandy@healthtech.com

FOR CONTENT AND SPEAKER SUGGESTIONS:

Rare Diseases/Gene Editing
Tanuja Koppal, PhD
Senior Director, Conferences
Cambridge Healthtech Institute
E: tkoppal@healthtech.com